您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > SPL-707
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SPL-707
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SPL-707图片
规格:98%
分子量:505.54
包装与价格:
包装价格(元)
250mg电议
500mg电议

产品介绍
SPL-707是有效的,选择性的和口服可用的信号肽肽酶样2a(SPPL2a)抑制剂,IC50值为80nM。
货号:ajcx12650
CAS:2195361-33-0
分子式:C27H28FN5O4
分子量:505.54
溶解度:Soluble in DMSO
纯度:98%
存储:Store at -20°C
库存:现货

Background:

SPL-707 is a potent, selective and orally available signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC50 of 80 nM.

SPL-707 shows 25-fold selectivity over SPP with an IC50 of 3.7 μM and some preference for SPPL2a over SPPL2b with a 3-fold selectivity, comparing IC50 values generated with comparable assay formats for the different proteases[1].

SPL-707 significantly inhibits processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses ≤10 mg/kg b.i.d. po. Oral dosing of SPL-707 for 11 days at ≥10 mg/kg b.i.d. recapitulates the phenotype seen in Sppl2a knockout (ko) and ENU mutant mice (reduced number of specific B cells and myeloid dendritic cells)[1].

[1]. Velcicky J, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. J Med Chem. 2018 Feb 8;61(3):865-880.

Protocol:

Cell experiment:

DNA vectors encoding human Notch1-VP16-Gal4 fusion protein and a Gal4-luciferase reporter for the γ-secretase RGA, or human SPPL2a, VP16-TNFa(aa1-76)-NTF substrate, and the Gal4-luciferase reporter plasmid for the SPPL2a RGA, are transiently transfected in HEK293 cells using FuGENE. After transfection, the cell suspensions are diluted and distributed to white solid 384-well plate at 10000 cells/50 μL/well. After 3 h, 200 nL of SPL-707 in DMSO is stamped into the wells in concentration response covering final inhibitor concentrations of 10 μM to 0.3 nM in triplicate. Subsequently, plates are incubated for 24 h at 37°C, 5% CO2 in a humidified incubator before the addition of 30 μL Bright Glo. After incubation for 5 min at rt, luminescence is measured and IC50 values are determined by plotting compound concentration vs normalized luminescence values[1].

Animal experiment:

Rats[1]Female Lewis rats receive SPL-707 (1, 3, 10, and 30 mg/kg b.i.d.; first dose at 0 h, second dose at 8 h). Then 16 h after the second dose (24 h in total), inhibition of SPPL2a is assessed by measuring CD74/p8 accumulation in blood and splenocyte extracts by Western blot analysis[1].Mice[1] Mice receive single oral doses of 150 mg/ kg 31 or 1, 3, 10, and 30 mg/kg 40. Then 16 h after dosing, inhibition of SPPL2a is assessed by measuring CD74/p8 accumulation in splenocyte lysates by Western blot analysis[1].

参考文献:

[1]. Velcicky J, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. J Med Chem. 2018 Feb 8;61(3):865-880.